Drug intelligence / Profile preview

DWJ1366

Development stage: Discontinued
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWJ1366 is a fixed-dose combination drug developed by Daewoong Pharmaceutical, consisting of two components, DWC20155 and DWC20156. It was investigated as an oral therapy for the treatment of gastritis and gastrointestinal ulcers. The precise mechanism of action has not been publicly defined, but it is classified as an antiulcer agent. Clinical development reached phase III in South Korea; however, trials were terminated due to lack of efficacy, and the program has since been discontinued[1][2].

Brand names: DWJ1366DWJ-1366DWJ 1366
Other names: DWJ 1366DWJ1366DWJ-1366

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on DWJ1366.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1366.

Explore the full profile